Journal of Nanomaterials
Volume 2015 (2015), Article ID 390358, 8 pages
http://dx.doi.org/10.1155/2015/390358

Research Article

Cisplatin Loaded Hyaluronic Acid Modified TiO₂ Nanoparticles for Neoadjuvant Chemotherapy of Ovarian Cancer

Enling Liu,¹ Yuxiu Zhou,² Zheng Liu,³ Jun Li,¹ Donghong Zhang,¹ Junchen Chen,¹ and Zhaohui Cai¹

¹Department of Obstetrics and Gynecology, Tangshan Worker Hospital, Hebei Medical University, Tangshan, Hebei 063000, China
²Department of Immunity, Tangshan Worker Hospital, Hebei Medical University, Tangshan, Hebei 063000, China
³Hebei Medical University, Shijiazhuang, Hebei 050000, China

Received 11 June 2015; Revised 2 July 2015; Accepted 15 July 2015

Academic Editor: Antonio Villaverde

Copyright © 2015 Enling Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Novel tumor-targeting titanium dioxide () nanoparticles modified with hyaluronic acid (HA) were developed to explore the feasibility of exploiting the pH-responsive drug release property of and the tumor-targeting ability of HA to construct a tumor-targeting cisplatin (CDDP) delivery system (HA-) for potential neoadjuvant chemotherapy of ovarian cancer. The experimental results indicated that CDDP release from the HA- nanoparticles was significantly accelerated by decreasing pH from 7.4 to 5.0, which is of particular benefit to cancer therapy. CDDP-loaded HA- nanoparticles increased the accumulation of CDDP in A2780 ovarian cancer cells via HA-mediated endocytosis and exhibited superior anticancer activity in vitro. In vivo real-time imaging assay revealed that HA- nanoparticles possessed preferable tumor-targeting ability which might potentially minimize the toxic side effects of CDDP in clinical application.

1. Introduction

Ovarian cancer is a commonly fatal disease which is responsible for 4% of deaths from cancer in women. Primary debulking surgery before initiation of chemotherapy has been the standard of care for patients with advanced ovarian cancer [1].

One of the most critical issues in neoadjuvant chemotherapy of ovarian cancer is the effectiveness of drug delivery. Conventional chemotherapeutic agents were distributed nonspecifically in the body when given intravenously. They affect both cancerous and normal cells, thereby limiting the dose achievable within the tumor and also resulting in suboptimal treatment due to excess toxicity [2]. The development of nanotechnology has shed light on tumor-targeted delivery of anticancer drugs. The nanosized particles can passively accumulate at the tumor site via the so-called enhanced permeability and retention effect [3]. Moreover, advanced tumor-targeting effect can be further achieved by attaching or grafting certain tumor-targeting ligand to the particles [4, 5]. Hyaluronic acid (HA), also called hyaluronan, is a naturally occurring polysaccharide present in the extracellular matrix and synovial fluids. In particular, since HA can specifically bind to various cancer cells, many studies have focused on the pharmaceutical applications of HA as a targeting ligand for anticancer therapeutics [6, 7]. In particular, ovarian cancer has been proved to be a cancer whose evolution process is closely related to HA [8, 9].

To date, a variety of nanocarriers have been successfully developed with various formulations and on the basis of many different materials. This includes polymer based polymeric micelles, lipid based liposomes, and some solid nanoparticles comprised of inorganic skeleton [10–12]. Titanium dioxide nanoparticles (TiO₂ NPs) have been proven to be a suitable candidate for biomedical applications due to their many merits such as the fact that TiO₂ NPs possess good optical and electronic properties and the catalyst is stable, nontoxic, cheap, and biologically and chemically inert [13, 14]. At the same time, the high surface area of TiO₂ NPs can guarantee preferable loading of drug [15]. As a result, TiO₂ NPs have been identified as a promising drug carrier in anticancer therapy [16, 17].

Among various clinical applied chemotherapy drugs, cisplatin (cis-diamminedichloroplatinum (II), CDDP) has been demonstrated to be a promising one which shows preferable anticancer effect on ovarian cancer and has already been adopted in neoadjuvant chemotherapy of ovarian cancer for many years [18, 19]. In this study, with the aim of effectively delivering CDDP to the ovarian cancer site, we employed TiO₂ NPs as a solid nano-sized vector. The TiO₂ NPs were functionalized with HA to formulate HA-TiO₂ nanoparticles with the ability to specifically bind with ovarian cancer cells. At last, the HA-TiO₂ nanoparticles were loaded with CDDP to construct a tumor-targeted delivery system with the hope to achieve preferable neoadjuvant chemotherapy of ovarian cancer.

2. Materials and Methods

2.1. Materials

Titanium (IV) isopropoxide (TIP) (95%) was obtained from Alfa Aesar (Lancs, UK). Pluronic block copolymer F127, hyaluronic acid (molecular weight  =  10 kDa), cisplatin (CDDP), coumarin-6 (C6), DiR iodide (DiR), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) were obtained from Sigma-Aldrich (St. Louis, MO, USA). All other solvents and chemicals used were from Nanjing Chemical reagent Co., Ltd., and of analytical grades.

2.2. Cell Culture

A2780 human ovarian cancer cells, obtained from the Cell Bank of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China), were maintained in RPMI 1640 medium (Sigma, St. Louis, MO) containing 10% (v/v) fetal bovine serum (Hyclone, USA), 100 U/mL penicillin G, and 100 μg/mL streptomycin with a humidified atmosphere of 5% (v/v) CO₂ and a temperature of 37°C.

2.3. Animal Model

Female BALB/c nude mice were purchased from Shanghai Laboratory Animal Center (SLAC, China) and maintained at standard conditions of temperature, humidity, and a 12 : 12 h light-dark cycle daily with free access to food and water. All animal experiments were conducted in strict accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals. The A2780 tumor-bearing mice models were established by inoculating a suspension of 1 × 10⁶ A2780 cells in 100 μL physiological saline into the subcutaneous dorsa of BALB/c nude mice. Tumor-bearing mice were included for study when the tumor volume reached 80–100 mm³ (calculated by the formula: , where and are the shortest and longest diameter, resp.).

2.4. Preparation of HA-TiO₂ Nanoparticles

2.4.1. Preparation of TiO₂ Nanoparticles

The TiO₂ nanoparticles were synthesized via a sol-gel route as previously reported [20]. F127 was selected as a structure-directing agent and TIP as a TiO₂ source. Briefly, 16 g F127 was dissolved in proper amount of ethanol and then mixed with 2.4 mL water (Milli-Q). Another 7.4 mL of TIP was added to the solution at ambient temperature with vigorous stirring for 1 h. After that, the solution was kept at room temperature without stirring for 12 h. Finally, 2 g precursor sample was dispersed in certain amount of ethanol and stirred for 2 h at 70°C. After stirring, samples were collected by centrifugation and extracted for three times in this way, followed by vacuum desiccation at 40°C overnight. Moreover, the resulting product was dried at 200°C for one day to remove ethanol and F127 completely.

2.4.2. Preparation of HA-TiO₂ Nanoparticles

80 mg of TiO₂ nanoparticles was suspended in HA phosphate buffer (PBS, pH 7.4, 10 mg/mL), and then the solution was stirred for 5 h at room temperature. These HA-TiO₂ nanoparticles were then collected by centrifugation (5000 g for 10 min) and were dried by vacuum desiccation.

2.5. Drug Loading

For a typical drug loading experiment, CDDP (2 mg) in 1 mL of methanol was added to 5 mL water/methanol (1 : 1, v/v) suspension of HA-TiO₂ nanoparticles (10 mg/mL). The above reaction mixture was continuously agitated with a stirrer at 50 g for 1 h to construct drug delivery system of CDDP-loaded HA-TiO₂ nanoparticles. CDDP-loaded HA-TiO₂ nanoparticles were isolated from the free-standing drug molecules through centrifugation at 5000 g for 30 minutes and the supernatant was determined by high-performance liquid chromatography (HPLC, Agilent 1200 series) to determine drug loading. The HPLC was loaded with ODS 120A column (4.6 × 250 mm) at a constant temperature of 45°C. The mobile phase consisted of 6 mM 1-octanesulfonate, 6 mM tetra-n-butylammonium hydrogen sulfate, and 20 mM KH₂PO₄, which was adjusted to pH 5.0 with 1 M NaOH. The applied flow rate was 0.7 mL/min. The spectrophotometric detection was set at 301 nm as described before [21]. Encapsulation efficiency and loading efficiency were calculated by the following equations:

2.6. Morphology, Particle Size, and Zeta Potential Analysis

The morphologies were observed by transmission electron microscopy (TEM) under a JEM-2100 Electron Microscope (JEOL, Tokyo, Japan). The size distributions, mean particle size, and polydispersity index (PDI) were assessed by dynamic light scattering (DLS) (Brookhaven Instruments Corp., USA) by measuring the autocorrelation function at 90°. The zeta potential of the nanoparticles was determined using a Zeta plus zeta potential analyzer (Brookhaven Instruments Corp., USA) at 25°C.

2.7. In Vitro Drug Release

Release behavior of CDDP from CDDP-loaded HA-TiO₂ nanoparticles was investigated at pH 5.0 (approximate pH in endosomes or lysosomes), pH 6.0 (pH of the environment around the tumor), and pH 7.4 (pH of physiological blood). CDDP-loaded HA-TiO₂ nanoparticles (20 mg) were dispersed in PBS (pH 7.4, 5 mL) and transferred into a dialysis bag (Spectra/Por, USA, WMCO 3500 Da). The dialysis bag was then immersed in 95 mL of PBS at different pH values and kept in a horizontal laboratory shaker maintained at 50 g and 37°C. At predetermined time points, sample (2 mL) of the medium was removed, the same volume of fresh medium was added. The amount of released CDDP in the medium was then determined by HPLC.

2.8. Cellular Uptake of HA-TiO₂ Nanoparticles

To evaluate the cellular uptake of TiO₂ nanoparticles and HA-TiO₂ nanoparticles in A2780 human ovarian carcinoma cell line, fluorescent probe coumarin-6 (C6) was encapsulated in the nanoparticles in the same way as for the CDDP-loaded nanoparticles (the C6 loading of the two formulations was 0.17% which was determined by fluorescence spectrophotometer (RF-5301 PC; Shimadzu, Japan)). A2780 cells were seeded in confocal dishes ( mm) at a density of 1 × 10⁵ cells/dish and cultured overnight. The dishes were then replaced with 1 mL of the serum-free medium containing C6-loaded TiO₂ nanoparticles and C6-loaded HA-TiO₂ nanoparticles (C6 content: 500 ng/mL). To investigate whether nanoparticles were taken up through HA-mediated endocytosis, cells were incubated with 10 mg/mL of free HA polymer for 1 hour prior to nanoparticles addition. After 2, 4, and 6 hours of incubation, the culture media were removed, and the cells were rinsed with PBS thrice. Subsequently, the cells were fixed with 4% formaldehyde for 20 minutes and observed under a Leica confocal laser scanning microscope (CLSM) (TCS SP5; Leica, Germany). The fluorescence intensity was quantitatively determined by flow cytometer (FCM) (BD FACSCalibur, USA).

2.9. Assay of Anticancer Activity

Cytotoxicity of free nanoparticles and CDDP-loaded nanoparticles was studied. The A2780 cells were harvested by trypsinization and resuspended at a concentration of 1 × 10⁴ cells/mL in fresh culture medium. The cells were then seeded into 96-well flat-bottomed tissue-culture plates and incubated for 48 h in the presence of different samples. The free TiO₂ nanoparticles and free HA-TiO₂ nanoparticles were diluted with culture medium to obtain concentrations in the range of 1–50 μg/mL; CDDP sample solutions were diluted with culture medium to obtain CDDP concentrations in the range of 0.01–10 μg/mL. The cytotoxic effects of free TiO₂ nanoparticles, free HA-TiO₂ nanoparticles, CDDP, CDDP-loaded TiO₂ nanoparticles, and CDDP-loaded HA-TiO₂ nanoparticles were evaluated by adding a mixture of 100 μL of each sample and 100 μL of culture medium to each well. After 48 h of incubation, cell viability was evaluated by MTT assay.

2.10. In Vivo Distribution of HA-TiO₂ Nanoparticles

Near-infrared fluorescent (NIR) probe DiR iodide (DiR) was encapsulated in the nanoparticles in the same way as for the C6-loaded nanoparticles. The A2780 tumor-bearing mice were injected in the tail vein with DiR-loaded HA-TiO₂ nanoparticles (as the experimental group) and DiR-loaded TiO₂ nanoparticles (as the control group), respectively (at a concentration of 1.0 mg/mL, 200 μL). The in vivo tumor-targeting efficacy and biodistribution of different nanoparticles at predetermined time intervals were evaluated using In Vivo Imaging System (FXPRO, Kodak, USA) equipped with DiR filter sets (excitation/emission, 720/790 nm). After live imaging, the mice were sacrificed, and the tumor tissues as well as major organs (heart, liver, spleen, lung, and kidney) were excised for ex vivo imaging using the same imaging system.

3. Results and Discussion

3.1. Characterization of Nanoparticles

TEM images of TiO₂ nanoparticles and HA-TiO₂ nanoparticles are displayed in Figure 1(a). Although observed TiO₂ nanoparticles had a spherical shape with a diameter of about 25 nm, most of the TiO₂ nanoparticles appeared to be agglomerated and formed large particle with a diameter over 300 nm, which might be due to their large surface area and high interface energy. Compared with TiO₂ nanoparticles, HA-TiO₂ nanoparticles showed no agglomeration with a diameter around 30 nm. The particle size measurement also confirmed the results. As depicted in Figure 1(b), the size of TiO₂ nanoparticles appeared to have multiple size sections with a PDI over 0.4 and a mean diameter of 277 nm. In contrast, the HA-TiO₂ nanoparticles were more homogeneous with a diameter of 50 nm and a PDI of 0.123. The zeta potential results (Figure 1(c)) showed that HA-TiO₂ nanoparticles exerted higher surface charge than TiO₂ nanoparticles (−30 mV versus –12 mV). It has been reported that applying polyanion on the surface of nanoparticles can change their surface to be negatively charged [22]. As in our experiment, the HA modification increased the surface charge of TiO₂ nanoparticles, which might, in turn, alleviate the agglomeration and result in well dispersity of HA-TiO₂ nanoparticles. On the other hand, it is well known that small particle size, especially under 100 nm, is expected to prevent uptake by the reticuloendothelial system and facilitates extravasation at leaky sites of capillaries, leading to passive accumulation in certain tissues like tumor [23]. Our results indicated that the HA-TiO₂ nanoparticles had dimensions suitable for escaping rapid renal excretion, as well as avoiding components of the reticular endothelial system. Thus, potentially passive targeting of drugs to tumors was facilitated via enhanced permeation and retention effect, and drug accumulation in tumor cells after endocytosis might be increased.

(a)

(b)

(c)

Figure 1: TEM images (a) of TiO₂ nanoparticles (left) and HA-TiO₂ nanoparticles (right). Particle size distribution (b) of TiO₂ nanoparticles (left) and HA-TiO₂ nanoparticles (right). Mean particle size and zeta potential measurements (c) of TiO₂ nanoparticles and HA-TiO₂ nanoparticles. Scale bar: 50 nm.

3.2. Drug Loading

CDDP is a cell cycle nonspecific antineoplastic drug and used to treat various types of cancers, including sarcomas, some carcinomas (e.g., small cell lung cancer and ovarian cancer), and lymphomas and germ cell tumors. High dosages are required for an effective therapy. Reports have demonstrated that TiO₂ nanotubes in aqueous solution showed high affinity to CDDP, which could suck CDDP and retains it in the TiO₂ skeleton [24]. Herein, we employed TiO₂ nanoparticles as a carrier to load CDDP. Encapsulation efficiency and loading efficiency of CDDP-loaded HA-TiO₂ nanoparticles were assessed and calculated as and , respectively (data not shown). Results show that CDDP-loaded HA-TiO₂ nanoparticles might efficiently act as anticancer drug delivery system (DDS).

3.3. pH-Responsive Drug Release

Drug entrapment can be possible through complexation with transition metal ions. Since transition metals show variable valence with respect to pH of its surrounding environment, it is possible that the drug release can be regulated to site specificity through adjustment of pH in case of the transition metal encapsulating the drug [25]. Therefore, we were with the opinion that TiO₂ nanoparticles loaded with CDDP could be able to be directed for cancerous cells as its pH is acidic in nature. Moreover, the release might be further enhanced in endosomes and lysosomes so that the effective toxicity will be enhanced.

As shown in Figure 2, release profile of CDDP depended on both the medium pH and release time. Drug release at pH 7.4 was slow and sustained, with release ratio within 22% in 48 hours. However, at lower pH, CDDP release rate became much faster, with approximately 68% (pH 6.0) and 90% (pH 5.0) of the drug released within 48 hours. Protonation of the drug (dissociation of CDDP-loaded TiO₂ nanoparticles) occurred at lower pH, which released absorbed CDDP drug molecules into the medium. It was hypothesized that, at normal physiological conditions (pH 7.4), most CDDP will remain in the carrier for a considerable time period, suggesting the potential for prolonged CDDP retention time in blood circulation, and thereby could greatly reduce the side effects of CDDP to normal tissues. Moreover, once CDDP-loaded TiO₂ nanoparticles are taken up by tumor cells via endocytotic process, an increased release might occur at lower local pH, that is, surrounding the tumor site or inside the endosome and lysosome of tumor cells, which might lead to significant improvement of therapeutic effect.

Figure 2: In vitro CDDP release behavior of CDDP-loaded HA-TiO₂ nanoparticles at pH 7.4, 6.0, and 5.0.

3.4. Cellular Uptake of HA-TiO₂ Nanoparticles

It has been demonstrated that the HA segment exposed to the surface of the nanoparticles can target some of the receptors which were excessively expressed in ovarian cancer cells [26]. In order to address the concept of HA mediated-targeting, C6 as a model fluorescent molecule was entrapped in the nanoparticles and the endocytosis process was monitored by fluorescence microscopy. The fluorescence intensity of C6 was further quantified by FCM at different time points. A2780 ovarian cancer cells were employed for cellular uptake evaluation [27].

As shown in Figure 3(a), CLSM revealed higher green C6 fluorescence signals in the cells of HA-TiO₂ group than that of TiO₂ group, indicating that HA-TiO₂ nanoparticles have more effectively entered the cells. It was worth mentioning that under the same conditions, the C6-loaded nanoparticles displayed remarkably higher intensity compared with free C6, suggesting that DDS can enhance the uptake efficiency of free drugs. The intracellular uptake was also quantitatively analyzed by FCM, as displayed in Figure 3(b). The fluorescence intensities of C6-loaded TiO₂ nanoparticles and C6-loaded HA-TiO₂ nanoparticles were approximately 4.21-fold and 8.31-fold higher, respectively, than that of free C6 after incubation for 4 hours. However, after HA pretreatment, the fluorescence intensity of C6-loaded HA-TiO₂ group suffered a great decline while the fluorescence intensity of C6-loaded TiO₂ group remained almost the same level. These results clearly suggest that C6-loaded HA-TiO₂ nanoparticles were internalized into cells via HA-mediated endocytosis. In addition, the fluorescence signal gradually became stronger with extended incubation time, indicating that the intracellular uptake of the nanoparticles was in accordance with a time-dependent manner.

(a)

(b)

Figure 3: In vitro cellular internalization evaluation of HA-TiO₂ nanoparticles. (a) Cellular uptake of free C6, C6-loaded TiO₂ nanoparticles, and C6-loaded HA-TiO₂ nanoparticles with and without pretreatment with free HA polymer, in A2780 cells as a function of the incubation time (2 and 4 hours at 37°C). (b) Quantitative flow cytometric analysis of the intracellular uptake of free C6, C6-loaded TiO₂ nanoparticles, and C6-loaded HA-TiO₂ nanoparticles with and without HA pretreatment in A2780 cells for 2, 4, and 6 hours of incubation. Data were expressed as mean ± SD (). and . Scale bar: 20 μm.

3.5. Assay of Anticancer Activity

To further explore the anticancer efficiency of the novel pH-responsive DDS based on TiO₂ nanoparticles for CDDP, A2780 cells were cultured with free CDDP at different concentrations (0.01, 0.1, 1, and 10 μg/mL) and CDDP-loaded TiO₂ nanoparticles and CDDP-loaded HA-TiO₂ nanoparticles with equivalent CDDP concentration for 48 hours. Cytotoxicity results were estimated by MTT assay (Figure 4). At the same time, cytotoxicity test of the nanoparticles without CDDP is also conducted as the first-level evaluation (nanoparticle concentrations range from 1 to 50 μg/mL, Figure 4(a)). When treated by TiO₂ nanoparticles and HA-TiO₂ nanoparticles, more than 90% of the cells survived at the highest dose, which is consistent with a previous report [28]. The low cytotoxicity of TiO₂ nanoparticles and HA-TiO₂ nanoparticles thus ensures a wide potential range of applications in the field of biomedical science and cancer therapy. Compared with CDDP alone, CDDP-loaded TiO₂ nanoparticles showed certain cytotoxicity on A2780 cells. Moreover, CDDP-loaded HA-TiO₂ nanoparticles exhibited a more increased cytotoxicity, which was even superior to CDDP alone. Results also demonstrated that, with increasing concentrations of CDDP, lethality increased, suggesting a dose-dependent effect in vitro. Increased cytotoxicity of CDDP-loaded HA-TiO₂ nanoparticles might be due to the improved CDDP cellular uptake mediated by HA (as illustrated above) and to the burst release of CDDP from HA-TiO₂. At normal physiological conditions (pH 7.4), it is expected from the release experiment that most CDDP in HA-TiO₂ nanoparticles will remain in the carrier for a considerable time period. In the endocytosis process, pH values drop from 7.4 to 6.5 or even as low as 4.5. At this low pH, protonation of the drug occurs. Protonation will then trigger the release of absorbed drug molecules which facilitates the drug release process. Consequently, a burst release of CDDP from CDDP-loaded HA-TiO₂ nanoparticles occurs once the carrier is taken up by the tumor cells via endocytic process. Therefore, a sufficiently high concentration of CDDP can be generated within a reasonably short period of time, thereby greatly promoting the cell-killing effects efficiently.

(a)

(b)

Figure 4: (a) Cell viabilities of A2780 cells incubated with free TiO₂ nanoparticles and HA-TiO₂ nanoparticles at various concentrations (1–50 μg/mL) for 48 h. (b) Cell viabilities of A2780 cells incubated with free CDDP, CDDP-loaded TiO₂ nanoparticles, and CDDP-loaded HA-TiO₂ nanoparticles at various concentrations (0.01–10 μg/mL) for 48 h. Data were expressed as mean ± SD (). and .

3.6. In Vivo Imaging

HA modification was expected to increase the accumulation of HA-TiO₂ nanoparticles at the tumor site. Here, the fluorescence intensity of DiR was monitored using an NIR fluorescence imaging system for 6 h to evaluate the targeting ability of different nanoparticles in A2780 tumor-bearing nude mice. Figure 5(a) showed the in vivo images at the tumor site after intravenous injection of complexes at different time points. Images recorded at 1, 3, and 6 h showed significant differences in targeting efficacy between TiO₂ nanoparticles and HA-TiO₂ nanoparticles. In detail, the fluorescence intensity of HA-TiO₂ nanoparticles at the tumor site was all markedly stronger than that of TiO₂ nanoparticles at each time point. The fluorescence intensity of M HA-TiO₂ nanoparticles at 1 h, especially, was almost the same as that of TiO₂ nanoparticles at 6 h, indicating the preferable accumulation of HA-TiO₂ nanoparticles at the tumor site. The powerful tumor targetability of HA-TiO₂ nanoparticles might be ascribed to a combination of EPR effect and HA-mediated endocytosis mechanism. The ex vivo imaging of tumor and major organs demonstrated that TiO₂ nanoparticles were mainly distributed in the liver and kidney, which, due to their large particles size and low surface charge, might in part be attributed to their poor tumor targetability.

(a)

(b)

Figure 5: (a) In vivo time-dependent tumor-targeting images after intravenous injection of DiR-loaded TiO₂ nanoparticles and DiR-loaded HA-TiO₂ nanoparticles in A2780 tumor-bearing mice and (b) representative ex vivo NIR fluorescence images of dissected tumors and major organs at 6 h after injection.

4. Conclusion

In summary, a new type of tumor-targeting DDS (HA-TiO₂) was developed through modification of TiO₂ with HA to explore the potential feasibility of modified TiO₂ in targeted CDDP delivery. The experimental results indicated that CDDP release from the HA-TiO₂ nanoparticles was significantly accelerated by decreasing pH from 7.4 to 5.0, which is of particular benefit to cancer therapy. CDDP-loaded HA-TiO₂ nanoparticles increased the accumulation of CDDP in A2780 ovarian cancer cells via HA-mediated endocytosis and exhibited superior anticancer activity in vitro. In vivo real-time imaging assay revealed that HA-TiO₂ nanoparticles possessed preferable tumor-targeting ability which might potentially minimize the toxic side effects of CDDP in clinical application.

Conflict of Interests

The authors report no conflict of interests.

Acknowledgment

The authors greatly acknowledge the financial support from Tangshan Science and Technology Research Projects (no. 111302097b).

References

I. Vergote, C. G. Tropé, F. Amant et al., “Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer,” The New England Journal of Medicine, vol. 363, no. 10, pp. 943–953, 2010.

M. Vanneman and G. Dranoff, “Combining immunotherapy and targeted therapies in cancer treatment,” Nature Reviews Cancer, vol. 12, no. 4, pp. 237–251, 2012.

H. Maeda, “The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting,” Advances in Enzyme Regulation, vol. 41, no. 1, pp. 189–207, 2001.

R. Pasqualini, E. Koivunen, and E. Ruoslahti, “|[alpha]| v Integrins as receptors for tumor targeting by circulating ligands,” Nature Biotechnology, vol. 15, no. 6, pp. 542–546, 1997.

C. Wang, X. Bao, X. Ding et al., “A multifunctional self-dissociative polyethyleneimine derivative coating polymer for enhancing the gene transfection efficiency of DNA/polyethyleneimine polyplexes in vitro and in vivo,” Polymer Chemistry, vol. 6, no. 5, pp. 780–796, 2015.

K. Y. Choi, H. Chung, K. H. Min et al., “Self-assembled hyaluronic acid nanoparticles for active tumor targeting,” Biomaterials, vol. 31, no. 1, pp. 106–114, 2010.

Y. Lee, H. Lee, Y. B. Kim et al., “Bioinspired surface immobilization of hyaluronic acid on monodisperse magnetite nanocrystals for targeted cancer imaging,” Advanced Materials, vol. 20, no. 21, pp. 4154–4157, 2008.

J. Mikuła-Pietrasik, P. Sosińska, and K. Ksiązek, “Resveratrol inhibits ovarian cancer cell adhesion to peritoneal mesothelium in vitro by modulating the production of α5β1 integrins and hyaluronic acid,” Gynecologic Oncology, vol. 134, no. 3, pp. 624–630, 2014.

L. Picaud, B. Thibault, E. Mery et al., “Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progression,” Journal of Ovarian Research, vol. 7, no. 1, article 40, 2014.

E. S. Lee, K. Na, and Y. H. Bae, “Polymeric micelle for tumor pH and folate-mediated targeting,” Journal of Controlled Release, vol. 91, no. 1-2, pp. 103–113, 2003.

T. Lian and R. J. Y. Ho, “Trends and developments in liposome drug delivery systems,” Journal of Pharmaceutical Sciences, vol. 90, no. 6, pp. 667–680, 2001.

I. I. Slowing, J. L. Vivero-Escoto, C.-W. Wu, and V. S.-Y. Lin, “Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers,” Advanced Drug Delivery Reviews, vol. 60, no. 11, pp. 1278–1288, 2008.

D. Chowdhury, A. Paul, and A. Chattopadhyay, “Photocatalytic polypyrrole-TiO₂-nanoparticles composite thin film generated at the air-water interface,” Langmuir, vol. 21, no. 9, pp. 4123–4128, 2005.

Y. Masuda, W.-S. Seo, and K. Koumoto, “Deposition mechanism of anatase TiO₂ from an aqueous solution and its site-selective deposition,” Solid State Ionics, vol. 172, no. 1–4, pp. 283–288, 2004.

H. Jiang, T. Wang, L. Wang et al., “Development of an amorphous mesoporous TiO₂ nanosphere as a novel carrier for poorly water-soluble drugs: effect of different crystal forms of TiO₂ carriers on drug loading and release behaviors,” Microporous & Mesoporous Materials, vol. 153, pp. 124–130, 2012.

P. J. A. Borm and W. Kreyling, “Toxicological hazards of inhaled nanoparticles—potential implications for drug delivery,” Journal of Nanoscience & Nanotechnology, vol. 4, no. 5, pp. 521–531, 2004.

G. D. Venkatasubbu, S. Ramasamy, V. Ramakrishnan, and J. Kumar, “Folate targeted PEGylated titanium dioxide nanoparticles as a nanocarrier for targeted paclitaxel drug delivery,” Advanced Powder Technology, vol. 24, no. 6, pp. 947–954, 2013.

J. D. Hainsworth, W. W. Grosh, L. S. Burnett, H. W. Jones III, S. N. Wolff, and F. A. Greco, “Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration,” Annals of Internal Medicine, vol. 108, no. 2, pp. 165–170, 1988.

O. Rixe, W. Ortuzar, M. Alvarez et al., “Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel,” Biochemical Pharmacology, vol. 52, no. 12, pp. 1855–1865, 1996.

T. Wang, H. Jiang, L. Wan et al., “Potential application of functional porous TiO₂ nanoparticles in light-controlled drug release and targeted drug delivery,” Acta Biomaterialia, vol. 13, pp. 354–363, 2015.

J.-H. Kim, Y.-S. Kim, K. Park et al., “Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice,” Journal of Controlled Release, vol. 127, no. 1, pp. 41–49, 2008.

C. Wang, M. Li, T. Yang et al., “A self-assembled system for tumor-targeted co-delivery of drug and gene,” Materials Science and Engineering: C, vol. 56, pp. 280–285, 2015.

A. Lavasanifar, J. Samuel, and G. S. Kwon, “Poly(ethylene oxide)-block-poly(L-amino acid) micelles for drug delivery,” Advanced Drug Delivery Reviews, vol. 54, no. 2, pp. 169–190, 2002.

X. L. Xiao, L. X. Yang, M. X. Guo, C. F. Pan, Q. Y. Cai, and S. Z. Yao, “Biocompatibility and in vitro antineoplastic drug-loaded trial of titania nanotubes prepared by anodic oxidation of a pure titanium,” Science in China, Series B: Chemistry, vol. 52, no. 12, pp. 2161–2165, 2009.

H. Zhang, C. Wang, B. Chen, and X. Wang, “Daunorubicin-TiO₂ nanocomposites as a ‘smart’ pH-responsive drug delivery system,” International Journal of Nanomedicine, vol. 7, pp. 235–242, 2012.

S. Abbad, C. Wang, A. Waddad, H. Lv, and J. Zhou, “Preparation, in vitro and in vivo evaluation of polymeric nanoparticles based on hyaluronic acid-poly(butyl cyanoacrylate) and D-alpha-tocopheryl polyethylene glycol 1000 succinate for tumor-targeted delivery of morin hydrate,” International Journal of Nanomedicine, vol. 10, pp. 305–320, 2015.

A. Somasunderam, V. Thiviyanathan, T. Tanaka et al., “Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44,” Biochemistry, vol. 49, no. 42, pp. 9106–9112, 2010.

H. Zhang, H. Jiang, H. Wang, J. Zhao, B. Chen, and X. Wang, “Ultrasound mediated drug-loaded nanoparticles crossing cell membranes as a new strategy to reverse cancer multidrug resistance,” Journal of Nanoscience and Nanotechnology, vol. 11, no. 3, pp. 1834–1840, 2011.